cat no | io1063
A rapidly maturing, physiologically relevant, functional system for investigating the role of the APP London mutation in early-onset Alzheimer's disease (AD). This in vitro disease cell model recapitulates an increased ratio of amyloid beta peptides A𝛽42:40, as observed in AD.
ioGlutamatergic Neurons APP V717I/V717I are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered homozygous V717I mutation in the APP gene encoding amyloid precursor protein.
This disease model is part of an Alzheimer's disease panel of human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. Two additional clones for the APP V717I hom mutation are available for scientists who wish to repeat their experiments in multiple independent clones, please enquire. All disease models are genetically matched to the wild-type control, ioGlutamatergic Neurons. Additional mutations in the AD panel include heterozygous APP V717I, and heterozygous and homozygous APP KM670/671NL and PSEN1 M146L, alongside AD-relevant mutations in ioGABAergic Neurons and ioMicroglia.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Disease related phenotype
Increased ratio of A𝛽42:40 peptides compared to the genetically matched control, measured by immunoassay.
Make True Comparisons
Pair the Alzheimer's disease model cells with the wild type glutamatergic neurons to investigate the impact of the APP missense mutation.
Quick
The disease model cells and genetically matched control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
ioGlutamatergic Neurons APP V717I/V717I express neuron-specific markers comparably to the wild type control
ioGlutamatergic Neurons APP V717I/V717I form structural neuronal networks by day 11
ioGlutamatergic Neurons APP V717I/V717I demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic cell programming
bit.bio
V11
bit.bio
2024
Professor Deepak Srivastava
Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders
King’s College London
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Chakraborty et al
Nature Communications
2023
Featuring ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Qiaojin Lin et al
The EMBO Journal
2023
Featuring opti-ox powered hiPSC-derived glutamatergic neurons with constitutive expression of Cas9
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Further your disease research by pairing our wild type cells with isogenic disease models.